Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Operations (2016 - 2025)

Altimmune (ALT) has disclosed Cash from Operations for 16 consecutive years, with 19448000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 6.48% to 19448000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 67535000.0 through Dec 2025, up 15.42% year-over-year, with the annual reading at 67535000.0 for FY2025, 15.42% up from the prior year.
  • Cash from Operations for Q4 2025 was 19448000.0 at Altimmune, down from 11897000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 11897000.0 in Q3 2025, with the low at 27118000.0 in Q3 2024.
  • Average Cash from Operations over 5 years is 18200850.0, with a median of 18186500.0 recorded in 2024.
  • The sharpest move saw Cash from Operations plummeted 350.13% in 2021, then skyrocketed 56.13% in 2025.
  • Over 5 years, Cash from Operations stood at 21967000.0 in 2021, then increased by 21.22% to 17306000.0 in 2022, then rose by 4.47% to 16533000.0 in 2023, then fell by 10.48% to 18265000.0 in 2024, then fell by 6.48% to 19448000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 19448000.0, 11897000.0, and 19350000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.